Rep. Gilbert Ray Cisneros, Jr. Acquires Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on August 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
• Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
• Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
• Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO traded down $0.04 during midday trading on Friday, reaching $33.60. The company’s stock had a trading volume of 750,165 shares, compared to its average volume of 816,193. The stock has a market capitalization of $2.01 billion, a P/E ratio of -4.79 and a beta of 0.60. The firm has a 50 day moving average price of $35.26 and a 200-day moving average price of $32.03. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post -5.82 EPS for the current year.

Analysts Set New Price Targets

AGIO has been the topic of several research reports. HC Wainwright lifted their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. JPMorgan Chase & Co. raised their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Citigroup boosted their price objective on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Royal Bank Of Canada lifted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.25.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 30,000 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the sale, the insider owned 54,645 shares in the company, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Sei Investments Co. raised its holdings in shares of Agios Pharmaceuticals by 342.8% during the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after acquiring an additional 49,198 shares in the last quarter. SCS Capital Management LLC purchased a new position in Agios Pharmaceuticals during the 2nd quarter valued at $22,743,000. Seven Fleet Capital Management LP bought a new position in Agios Pharmaceuticals in the 4th quarter worth $864,000. GW&K Investment Management LLC lifted its position in shares of Agios Pharmaceuticals by 41.5% in the 4th quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock worth $32,863,000 after purchasing an additional 354,359 shares during the period. Finally, Erste Asset Management GmbH lifted its holdings in Agios Pharmaceuticals by 1.4% in the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after buying an additional 40,000 shares during the period.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults.